Outlook Therapeutics (OTLK) Q2 2026 earnings summary

Executive summary

• LYTENAVA (bevacizumab gamma) launched commercially in Germany and the UK in June 2025, expanded into Austria in 2026, and entered a new distribution agreement in Switzerland, with further EU launches planned; U.S. FDA approval remains pending after multiple CRLs and a formal dispute resolution request in April 2026, with a decision expected in May 2026.

• Net loss for the six months ended March 31, 2026 was $27.5 million, with negative net revenue due to increased returns reserves and administrative fees; cash and cash equivalents were $7.7 million at quarter-end.

• There is substantial doubt about the ability to continue as a going concern, with additional financing required to fund operations and commercialization efforts.

• Launched a real-world evidence study in Germany to support LYTENAVA's value proposition and reimbursement efforts.

Financial highlights

• Six months ended March 31, 2026: net revenue was negative $1.1 million, primarily due to increased returns reserves from lower-than-forecasted sell-through in the UK; Q2 FY2026 net loss attributable to common stockholders was $4.5 million ($0.05 per share), and adjusted net loss was $14.1 million ($0.16 per share).

• Research and development expenses decreased by $6.0 million year-over-year, mainly due to lower costs for the NORSE EIGHT clinical trial; Q2 FY2026 R&D expenses were $4.5 million.

• Selling, general and administrative expenses decreased by $1.8 million year-over-year, driven by lower compensation and professional fees, partially offset by higher European commercial expenses; Q2 FY2026 SG&A was $9.5 million.

• Net cash used in operating activities was $22.8 million for the six months ended March 31, 2026; net cash provided by financing activities was $22.4 million.

• Cash and cash equivalents as of March 31, 2026, were $7.7 million, excluding $4.2 million raised in April 2026.

Outlook and guidance

• Additional financing is required to fund operations through the next 12 months; management is evaluating licensing, partnerships, equity, and debt options.

• Awaiting FDA decision on the formal dispute resolution request for U.S. approval of ONS-5010/LYTENAVA, which could enable the first FDA-approved ophthalmic bevacizumab in the U.S.; expects 12 years of regulatory exclusivity if approved.

• Plans to expand commercial launches in additional EU countries, including the Netherlands and Ireland in late 2026, Switzerland in 2027, and further European markets.